When Does PML Risk Begin After Stopping Tysabri? Understanding the Timeline

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one developed progressive multifocal leukoencephalopathy after stopping Tysabri, you know the symptoms can be devastating. The timing of onset relative to the last dose is crucial for diagnosis and documentation. This page explains the PML timeline after Tysabri cessation, supported by the long-standing tradition of evidence-based medical knowledge.

The Medical Link Between Tysabri and PML

The medical literature establishes a clear and serious association between the use of Tysabri (natalizumab) and the development of Progressive Multifocal Leukoencephalopathy (PML), a rare but often fatal brain infection. For patients in Virginia who have been harmed, understanding the clinical presentation, the pharmacological mechanism, and the legal context of settlements is critical, particularly given the statute of limitations that governs claims. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV), which typically only occurs in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be insidious, with symptoms that may include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and, in later stages, seizures and severe disability. Diagnosis is typically confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in the cerebrospinal fluid via polymerase chain reaction (PCR). The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a monoclonal antibody that works by binding to alpha-4 integrin on the surface of immune cells, preventing them from crossing the blood-brain barrier. This mechanism reduces inflammation in the central nervous system, which is beneficial for treating relapsing forms of multiple sclerosis (MS) and Crohn's disease (CD) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, by inhibiting immune surveillance in the brain, Tysabri creates an environment where the JC virus can reactivate and cause PML. The mechanistic pathway linking Tysabri to PML is therefore rooted in this immunosuppressive effect within the central nervous system. The FDA-approved prescribing information for Tysabri includes a boxed warning that explicitly states: "TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations and Statute of Limitations in Virginia

The adequacy of these warnings has been a central issue in litigation. While the boxed warning and TOUCH program are extensive, questions have been raised about whether patients and physicians were fully informed of the magnitude of the risk, particularly in the context of long-term therapy. For affected patients in Virginia, settlement considerations often depend on the timeline between exposure to Tysabri and the documented harm of PML. The latency period for PML can vary, with cases reported after a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This timeline is crucial for establishing causation and for determining whether a claim falls within Virginia's statute of limitations. In Virginia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery is often the date of diagnosis, but it can be earlier if symptoms were present and should have prompted investigation. Given the severe and progressive nature of PML, early diagnosis is critical, but the disease can be difficult to recognize in its initial stages. Patients who developed PML after taking Tysabri should consult with a legal professional promptly to assess whether their claim is timely. Settlement-related considerations for affected patients include the severity of the injury, the extent of medical expenses, lost wages, and pain and suffering. Because PML usually leads to death or severe disability, settlements in these cases can be substantial. However, the presence of the boxed warning and the TOUCH program may be used by the defense to argue that the risks were adequately communicated. Nonetheless, if a patient can demonstrate that the warnings were insufficient or that the manufacturer failed to take additional steps to prevent harm, a settlement may be warranted. In summary, the evidence clearly links Tysabri to PML through a well-understood mechanism, and the FDA has mandated strong warnings. For Virginia patients, the statute of limitations is a critical factor that must be addressed promptly. The timeline between exposure and harm, combined with the clinical presentation and diagnosis of PML, forms the basis for any legal claim. Patients should seek both medical and legal advice to navigate these complex issues.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery is often the date of diagnosis, but it can be earlier if symptoms were present and should have prompted investigation. It is crucial to consult with a legal professional promptly to assess whether your claim is timely.

How does Tysabri cause Progressive Multifocal Leukoencephalopathy (PML)?

Tysabri (natalizumab) is a monoclonal antibody that binds to alpha-4 integrin on immune cells, preventing them from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also inhibits immune surveillance, allowing the JC virus to reactivate and cause PML. The FDA-approved prescribing information includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.